Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

ADA heart failure evidence-based nutrition practice guideline.

BIBLIOGRAPHIC SOURCE(S)

  • American Dietetic Association (ADA). ADA heart failure: evidence-based nutrition practice guideline. Chicago (IL): American Dietetic Association (ADA); 2008. Various p. [162 references]

GUIDELINE STATUS

This is the current release of the guideline.

The guideline will undergo a complete revision every three to five years.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Ratings for the strength of the recommendations (Strong, Fair, Weak, Consensus, Insufficient Evidence), conclusion grades (I-V), and statement labels (Conditional versus Imperative) are defined at the end of the "Major Recommendations" field.

Heart Failure (HF) Medical Nutrition Therapy and Heart Failure

HF: Medical Nutrition Therapy (MNT) and Heart Failure

Referral to a registered dietitian for MNT is recommended whenever an individual has heart failure. A planned initial visit lasting at least 45 minutes and at least one to three planned follow-up visits (at least 30 minutes each) can lead to improved dietary pattern and quality of life and decreases in edema and fatigue. Along with optimal pharmacological management, MNT may also reduce hospitalizations.

Strong, Imperative

Recommendation Strength Rationale

  • Conclusion statement was Grade II

Heart Failure (HF) Protein Needs in Heart Failure Patients

HF: Protein Needs

In assessing protein needs for patients with HF, clinically stable depleted patients should have a daily intake of at least 1.37 g protein/kg and normally nourished patients should have a daily intake 1.12 g protein/kg in order to preserve their actual body composition or limit the effects of hypercatabolism. Research indicates that HF patients have significantly higher protein needs than those without HF, as measured by negative nitrogen balance.

Fair, Imperative

Recommendation Strength Rationale

  • Conclusion statement was Grade III

Heart Failure (HF) Energy Needs in Heart Failure Patients

In assessing energy needs for patients with HF, the majority of studies indicate that use of indirect calorimetry best determines energy needs. When indirect calorimetry is not possible consider starting with usual predictive equations and adjusting for increased catabolic state.

Fair, Imperative

Recommendation Strength Rationale

  • Conclusion statement was Grade III

Heart Failure (HF) Sodium and Fluid Restriction and Heart Failure

Fluid Intake

For patients with HF, fluid intake should be between 1.4 and 1.9 L (48 to 64 oz.) per day, depending on clinical symptoms (i.e., edema, fatigue, shortness of breath). Fluid restriction will improve clinical symptoms and quality of life.

Fair, Imperative

Sodium Intake

For patients with HF, sodium intake should be less than 2000 mg (2 g) per day. Sodium restriction will improve clinical symptoms (i.e., edema, fatigue) and quality of life.

Fair, Imperative

Recommendation Strength Rationale

  • Conclusion statement was Grade II

Heart Failure (HF) Folate, B12, and Heart Failure

HF: Folate and Heart Failure

The practitioner should encourage patients with HF to consume at least the daily reference intake (DRI) for folate through food and/or a combination of B6, B12, and folate supplementation. Folate supplementation given with other vitamins/minerals has been shown to have beneficial clinical HF outcomes.

Fair, Imperative

HF: B12 and Heart Failure

A multi-vitamin/mineral containing B12 or a combination of B6, B12 and folate could be recommended in HF patients. This level of B12 supplementation (200 to 500 micrograms daily), given with other vitamins/minerals, has been shown to have beneficial clinical HF outcomes.

Fair, Imperative

Recommendation Strength Rationale

  • Conclusion statement was Grade II

Heart Failure (HF) Thiamine Supplementation and Heart Failure

HF: Thiamine Supplementation

Since diuretic use can lead to thiamine deficiency in patients with HF, the practitioner should evaluate thiamine status. The practitioner should encourage the patient to consume at least the DRI through food and/or supplements. The practitioner should stay alert to future research involving thiamine.

Fair, Conditional

Recommendation Strength Rationale

  • Conclusion statement was Grade III

Heart Failure (HF) Magnesium Supplementation and Heart Failure

The practitioner should encourage patients with HF to consume at least the DRI for magnesium through food and/or supplements. Low levels of magnesium may be present in patients with HF and irregular heart rhythms may occur. The practitioner should stay alert to future research involving magnesium.

Fair, Conditional

Recommendation Strength Rationale

  • Conclusion statement was Grade II

Heart Failure (HF) Alcohol and Heart Failure

HF: Alcohol and Heart Failure

Current limited evidence does not justify encouraging those who do not drink alcohol to start doing so. If a patient currently drinks alcohol, and if not contraindicated, then a maximum of one drink per day for women and up to two drinks per day for men may be tolerated. This level of alcohol consumption has been demonstrated to not be harmful in HF patients.

Fair, Conditional

Recommendation Strength Rationale

  • Conclusion statement was Grade II

Heart Failure (HF) L-Arginine, Carnitine, Coenzyme Q10, and Hawthorn

HF: L-Arginine, Carnitine, Coenzyme Q10, and Hawthorn

If a patient inquires about or is currently taking L-arginine, carnitine, coenzyme Q10  or hawthorn supplements, then the practitioner may discuss the limited evidence available regarding clinical HF outcomes. Research is inconclusive. The practitioner should stay alert to future research involving these supplements.

Weak, Conditional

Recommendation Strength Rationale

  • Conclusion statements were Grades II and III

Definitions:

Conditional versus Imperative Recommendations

Recommendations can be worded as conditional or imperative statements. Conditional statements clearly define a specific situation, while imperative statements are broadly applicable to the target population without restraints on their pertinence. More specifically, a conditional recommendation can be stated in if/then terminology (e.g., If an individual does not eat food sources of omega-3 fatty acids, then 1g of EPA and DHA omega-3 fatty acid supplements may be recommended for secondary prevention).

In contrast, imperative recommendations "require," or "must," or "should achieve certain goals," but do not contain conditional text that would limit their applicability to specified circumstances. (e.g., Portion control should be included as part of a comprehensive weight management program. Portion control at meals and snacks results in reduced energy intake and weight loss).

Levels of Evidence

Strength of Evidence Elements Grade I

Good/Strong
Grade II

Fair
Grade III

Limited/Weak
Grade IV

Expert Opinion Only
Grade V

Grade Not Assignable
Quality
  • Scientific rigor/validity
  • Considers design and execution
Studies of strong design for question

Free from design flaws, bias and execution problems
Studies of strong design for question with minor methodological concerns

OR

Only studies of weaker study design for question
Studies of weak design for answering the question

OR

Inconclusive findings due to design flaws, bias or execution problems
No studies available

Conclusion based on usual practice, expert consensus, clinical experience, opinion, or extrapolation from basic research
No evidence that pertains to question being addressed
Consistency

Of findings across studies
Findings generally consistent in direction and size of effect or degree of association, and statistical significance with minor exceptions at most Inconsistency among results of studies with strong design

OR

Consistency with minor exceptions across studies of weaker designs
Unexplained inconsistency among results from different studies

OR

Single study unconfirmed by other studies
Conclusion supported solely by statements of informed nutrition or medical commentators NA
Quantity
  • Number of studies
  • Number of subjects in studies
One to several good quality studies

Large number of subjects studies

Studies with negative results having sufficiently large sample size for adequate statistical power
Several studies by independent investigators

Doubts about adequacy of sample size to avoid Type I and Type II error
Limited number of studies

Low number of subjects studies and/or inadequate sample size within studies
Unsubstantiated by published studies Relevant studies have not been done
Clinical Impact
  • Importance of studies outcomes
  • Magnitude of effect
Studied outcome relates directly to the question

Size of effect is clinically meaningful

Significant (statistical) difference is large
Some doubt about the statistical or clinical significance of effect Studies outcome is an intermediate outcome or surrogate for the true outcome of interest

OR

Size of effect is small or lacks statistical and/or clinical significance
Objective data unavailable Indicates area for future research
Generalizability

To population of interest
Studied population, intervention and outcomes are free from serious doubts about generalizability Minor doubts about generalizability Serious doubts about generalizability due to narrow or different study population, intervention or outcomes studied Generalizability limited to scope of experience NA

This grading system was based on the grading system from: Greer N, Mosser G, Logan G, Wagstrom Halaas G. A practical approach to evidence grading. Jt Comm. J Qual Improv. 2000; 26:700-712. In September 2004, The ADA Research Committee modified the grading system to this current version.

Criteria for Recommendation Rating

Statement Rating Definition Implication for Practice
Strong A Strong recommendation means that the workgroup believes that the benefits of the recommended approach clearly exceed the harms (or that the harms clearly exceed the benefits in the case of a strong negative recommendation), and that the quality of the supporting evidence is excellent/good (grade I or II)*. In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms. Practitioners should follow a Strong recommendation unless a clear and compelling rationale for an alternative approach is present.
Fair A Fair recommendation means that the workgroup believes that the benefits exceed the harms (or that the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong (grade II or III)*. In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms. Practitioners should generally follow a Fair recommendation but remain alert to new information and be sensitive to patient preferences.
Weak A Weak recommendation means that the quality of evidence that exists is suspect or that well-done studies (grade I, II, or III)* show little clear advantage to one approach versus another. Practitioners should be cautious in deciding whether to follow a recommendation classified as Weak, and should exercise judgment and be alert to emerging publications that report evidence. Patient preference should have a substantial influencing role.
Consensus A Consensus recommendation means that Expert opinion (grade IV)* supports the guideline recommendation even though the available scientific evidence did not present consistent results, or controlled trials were lacking. Practitioners should be flexible in deciding whether to follow a recommendation classified Consensus, although they may set boundaries on alternatives. Patient preference should have a substantial influencing role.
Insufficient Evidence An Insufficient Evidence recommendation means that there is both a lack of pertinent evidence (grade V)* and/or an unclear balance between benefits and harms. Practitioners should feel little constraint in deciding whether to follow a recommendation labeled as Insufficient Evidence and should exercise judgment and be alert to emerging publications that report evidence that clarifies the balance of benefit versus harm. Patient preference should have a substantial influencing role.

*Conclusion statements are assigned a grade based on the strength of the evidence. Grade I is good; grade II, fair; grade III, limited; grade IV signifies expert opinion only and grade V indicates that a grade is not assignable because there is no evidence to support or refute the conclusion. The evidence and these grades are considered when assigning a rating (Strong, Fair, Weak, Consensus, Insufficient Evidence - see chart above) to a recommendation.

Adapted by the American Dietetic Association from the American Academy of Pediatrics, Classifying Recommendations for Clinical Practice Guideline, Pediatrics. 2004;114;874-877.

CLINICAL ALGORITHM(S)

The following algorithms are provided in the original guideline document:

  • Heart failure nutrition guideline
  • Heart failure nutrition assessment
  • Heart failure nutrition diagnosis
  • Heart failure nutrition intervention
  • Heart failure nutrition monitoring and evaluation

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

The guideline contains conclusion statements that are supported by evidence summaries and evidence worksheets. These resources summarize the important studies (randomized controlled trials [RCTs], clinical studies, observational studies, cohort and case-control studies) pertaining to the conclusion statement and provide the study details.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • American Dietetic Association (ADA). ADA heart failure: evidence-based nutrition practice guideline. Chicago (IL): American Dietetic Association (ADA); 2008. Various p. [162 references]

ADAPTATION

The levels of evidence were based on the grading system from: Greer N, Mosser G, Logan G, Wagstrom Halaas G. A practical approach to evidence grading. Jt Comm. J Qual Improv. 2000; 26:700-712. In September 2004, The American Dietetic Association (ADA) Research Committee modified the grading system to this current version.

The grades of recommendation were adapted by the American Dietetic Association (ADA) from the American Academy of Pediatrics, Classifying Recommendations for Clinical Practice Guideline, Pediatrics. 2004;114;874-877.

DATE RELEASED

2008 Jul

GUIDELINE DEVELOPER(S)

American Dietetic Association - Professional Association

SOURCE(S) OF FUNDING

American Dietetic Association

GUIDELINE COMMITTEE

Heart Failure Evidence-Based Guideline Workgroup

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Workgroup Members: Toni Kuehneman, MS, RD, LMNT, Chair; Mark A. Dinga, MEd, RD, LDN; Patricia Davidson, MS, RD, CDE; Rita A. Frickel, MS, RD, LMNT; Mary Beth Russell, RD, LN, CDE; KC Wright, MS, RD, LD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

In the interest of full disclosure, American Dietetic Association (ADA) has adopted the policy of revealing relationships workgroup members have with companies that sell products or services that are relevant to this topic. Workgroup members are required to disclose potential conflicts of interest by completing the ADA Conflict of Interest Form. It should not be assumed that these financial interests will have an adverse impact on the content, but they are noted here to fully inform readers.

None of the work group members listed above disclosed potential conflicts of interest.

GUIDELINE STATUS

This is the current release of the guideline.

The guideline will undergo a complete revision every three to five years.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI Institute on November 5, 2008. The information was verified by the guideline developer on December 9, 2008.

COPYRIGHT STATEMENT

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo